{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:29:26Z","timestamp":1785464966598,"version":"3.56.0"},"reference-count":43,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0322-1","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T13:12:11Z","timestamp":1518441131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone"],"prefix":"10.1136","volume":"6","author":[{"given":"Muhammad Zubair","family":"Afzal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodwell","family":"Mabaera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1403-8128","authenticated-orcid":false,"given":"Keisuke","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"D Singh","year":"2011","unstructured":"Singh D, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881\u20135.","journal-title":"Ophthalmology"},{"key":"322_CR2","unstructured":"\u201cSkin Cancer Foundation.\u201d Uveal Melanoma: Diagnosis, Prognosis and Current Treatments for Primary and Metastatic Disease - SkinCancer.Org, www.skincancer.org\/publications\/the-melanoma-letter\/fall-2016-vol-34-no-3\/uveal-melanoma . Accessed 31 Aug 2017."},{"issue":"12","key":"322_CR3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","volume":"124","author":"Collaborative Ocular Melanoma Study Group","year":"2006","unstructured":"Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684\u201393. https:\/\/doi.org\/10.1001\/archopht.124.12.1684 .","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"322_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","volume":"138","author":"BS Hawkins","year":"2004","unstructured":"Hawkins BS, Collaborative Ocular Melanoma Study Group. The collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138(6):936\u201351. https:\/\/doi.org\/10.1016\/j.ajo.2004.07.006 .","journal-title":"Am J Ophthalmol"},{"key":"322_CR5","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/archopht.126.10.1413","volume":"126","author":"G Virgili","year":"2008","unstructured":"Virgili G, Gatta G, Ciccolallo L, et al. Survival in patients with uveal melanoma in Europe. Arch Ophthalmol. 2008;126:1413\u20138.","journal-title":"Arch Ophthalmol"},{"key":"322_CR6","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no 26. Arch Ophthalmol. 2005;123:1639\u201343.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"322_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0301-4738.154367","volume":"63","author":"S Kaliki","year":"2015","unstructured":"Kaliki S, Shields C, Shields J. Uveal melanoma: Estimating prognosis. Indian J Ophthalmol. 2015;63(2):93. https:\/\/doi.org\/10.4103\/0301-4738.154367 .","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"322_CR8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/cam4.133","volume":"2","author":"K Buder","year":"2013","unstructured":"Buder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2013;2(5):674\u201386. https:\/\/doi.org\/10.1002\/cam4.133 .","journal-title":"Cancer Med"},{"key":"322_CR9","unstructured":"Selumetinib granted Orphan Drug Designation by US FDA for treatment of uveal melanoma. (2015, April 17). Retrieved August 31, 2017, from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2015\/selumetinib-orphan-drug-designation-us-fda-uveal-melanoma-treatment-17042015.html"},{"key":"322_CR10","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1001\/jama.2014.6096","volume":"311","author":"RD Carvajal","year":"2014","unstructured":"Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014;311:2397\u2013405.","journal-title":"JAMA"},{"key":"322_CR11","doi-asserted-by":"publisher","unstructured":"Kelderman S, van der Soetekouw MK, van den Kooij AJ, et al. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch working group on immunotherapy of oncology. Acta Oncol. 2013; https:\/\/doi.org\/10.3109\/0284186X.2013.786839 .","DOI":"10.3109\/0284186X.2013.786839"},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"8549","DOI":"10.1200\/jco.2012.30.27_suppl.35","volume":"30","author":"SA Khan","year":"2012","unstructured":"Khan SA, Callahan M, Postow MA, et al. Ipilimumab in the treatment of uveal melanoma: the Memorial Sloan-Kettering Cancer Center experience. J Clin Oncol. 2012;30:8549. Dent Abstr","journal-title":"J Clin Oncol"},{"key":"322_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/CMR.0b013e32835b554f","volume":"23","author":"MA Khattak","year":"2013","unstructured":"Khattak MA, Fisher R, Hughes P, Gore M, Larkinv J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 2013;23:79\u201381.","journal-title":"Melanoma Res"},{"issue":"20","key":"322_CR14","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/cncr.28282","volume":"119","author":"JJ Luke","year":"2013","unstructured":"Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and University Hospital of Lausanne experience. Cancer. 2013;119(20):3687\u201395. https:\/\/doi.org\/10.1002\/cncr.28282 .","journal-title":"Cancer"},{"issue":"15_suppl","key":"322_CR15","doi-asserted-by":"crossref","first-page":"9588\u20139588","DOI":"10.1200\/JCO.2016.34.15_suppl.9588","volume":"34","author":"S Piperno-Neumann","year":"2016","unstructured":"Piperno-Neumann S, Servois V, Mariani P, et al. Activity of anti-PD1 drugs in uveal melanoma patients. J Clin Oncol. 2016;34(15_suppl):9588\u20139588.","journal-title":"J Clin Oncol"},{"issue":"21","key":"322_CR16","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi AP, Tasi KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344\u201353. https:\/\/doi.org\/10.1002\/cncr.30258 .","journal-title":"Cancer"},{"key":"322_CR17","doi-asserted-by":"publisher","unstructured":"Komatsubara KM, Carvajal RD. Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies. Curr Oncol Rep. 2017;19(7) https:\/\/doi.org\/10.1007\/s11912-017-0606-5 .","DOI":"10.1007\/s11912-017-0606-5"},{"issue":"24","key":"322_CR18","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","volume":"16","author":"B Damato","year":"2010","unstructured":"Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16(24):6083\u201392.","journal-title":"Clin Cancer Res"},{"key":"322_CR19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"322_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2016","unstructured":"Carvajal RD, Gary KS, Tongalp T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2016;101(1):38\u201344. https:\/\/doi.org\/10.1002\/cncr.30258 .","journal-title":"Br J Ophthalmol"},{"key":"322_CR21","volume-title":"SUMIT: Phase III, randomized, 89 placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma","author":"RD Carvajal","year":"2015","unstructured":"Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. SUMIT: Phase III, randomized, 89 placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma. San Francisco: Society for Melanoma Research Congress; 2015."},{"key":"322_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/OPTH.S28863","volume":"7","author":"PR Pereira","year":"2013","unstructured":"Pereira PR, Odashiro AN, Lim LA, et al. Current and emerging treatment options for uveal melanoma. Clin Ophthalmol. 2013;7:1669\u201382.","journal-title":"Clin Ophthalmol"},{"key":"322_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CMR.0b013e3283610586","volume":"23","author":"F Spagnolo","year":"2013","unstructured":"Spagnolo F, Grosso M, Picasso V, et al. Treatment of metastatic uveal melanoma with intravenous fotemustine. Melanoma Res. 2013;23:196\u20138.","journal-title":"Melanoma Res"},{"key":"322_CR24","doi-asserted-by":"crossref","unstructured":"Deo MA. Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients. J Clin Oncol. 2014;32 (Suppl): Abstract 3060","DOI":"10.1200\/jco.2014.32.15_suppl.3060"},{"key":"322_CR25","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","volume":"24","author":"M Maio","year":"2013","unstructured":"Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24:2911\u20135.","journal-title":"Ann Oncol"},{"key":"322_CR26","doi-asserted-by":"crossref","unstructured":"Rodriguez JMP, Ochoa de Olza M, Codes M, et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial. J Clin Oncol. 2014;32 (Suppl): Abstract 9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033"},{"key":"322_CR27","doi-asserted-by":"publisher","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","volume":"10","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One. 2015;10:e0118564.","journal-title":"PLoS One"},{"issue":"3","key":"322_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","volume":"26","author":"LA Kottschade","year":"2016","unstructured":"Kottschade LA, Robert RM, Svetomir NM, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26(3):300\u20133. https:\/\/doi.org\/10.1097\/CMR.0000000000000242 .","journal-title":"Melanoma Res"},{"key":"322_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"322_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","volume":"82","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Heinzerling L, Kahler KC, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017;82:56\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.038 .","journal-title":"Eur J Cancer"},{"key":"322_CR31","doi-asserted-by":"publisher","unstructured":"Karydis I, Chan PY, Wheater M, et al. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. Onco Immunol. 2016;5(5) https:\/\/doi.org\/10.1080\/2162402X.2016.1143997 .","DOI":"10.1080\/2162402X.2016.1143997"},{"key":"322_CR32","doi-asserted-by":"publisher","unstructured":"Chan PY, Hall P, Gordon H, et al. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res. 2017; https:\/\/doi.org\/10.1111\/pcmr.12607 .","DOI":"10.1111\/pcmr.12607"},{"key":"322_CR33","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375.","journal-title":"Ann Oncol"},{"key":"322_CR34","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O'Day","year":"2010","unstructured":"O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21:1712\u20137.","journal-title":"Ann Oncol"},{"key":"322_CR35","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/jco.2014.32.15_suppl.4504","volume":"32","author":"HJ Hammers","year":"2014","unstructured":"Hammers HJ, Plimack ER, Infante JR, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma. J Clin Oncol. 2014;32:3851\u20138. (suppl; abstr 4504)","journal-title":"J Clin Oncol"},{"key":"322_CR36","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691.","journal-title":"J Clin Oncol"},{"key":"322_CR37","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233.","journal-title":"Dig Dis Sci"},{"key":"322_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2206","volume":"29","author":"KD Chmiel","year":"2011","unstructured":"Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29:e237.","journal-title":"J Clin Oncol"},{"issue":"28","key":"322_CR39","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center. J Clin Oncol. 2015;33(28):3193\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"322_CR40","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2016","unstructured":"Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2016;35(7):785\u201392.","journal-title":"J Clin Oncol"},{"issue":"7","key":"322_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bjc.2017.274","volume":"117","author":"AM Hopkins","year":"2017","unstructured":"Hopkins AM, Rowland A, Kichenadasee G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 2017;117(7):913\u201320. https:\/\/doi.org\/10.1038\/bjc.2017.274 .","journal-title":"Br J Cancer"},{"key":"322_CR42","doi-asserted-by":"publisher","unstructured":"Fujii T, Colen RR, Bilen MA, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2017; https:\/\/doi.org\/10.1007\/s10637-017-0534-0 .","DOI":"10.1007\/s10637-017-0534-0"},{"issue":"4","key":"322_CR43","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2015","unstructured":"Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2015;22(4):886\u201394. https:\/\/doi.org\/10.1158\/1078-0432.ccr-15-1136 .","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0322-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T05:42:48Z","timestamp":1660455768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0322-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0322-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]},"assertion":[{"value":"18 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have any competing interests in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Consent was obtained before the treatment of the patient from all the therapeutic agents. No other ethical approvals were needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publishing the individual and clinical details of the patients as well as the publication of the de-identified images. The consent if held by the authors and is available for review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"13"}}